Maze Therapeutics, Inc.

NASDAQ:MAZE

Biotechnology

Healthcare
$31.20 +0.74%

+$0.18 today

Market cap
$1.71B
Beta
2.26
P/E (TTM)
-11.0
EPS (TTM)
-$2.27
52W Low $9.83High $53.65

Volume 0.71M

Average 0.84M

MAZE Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Maze Therapeutics, Inc.NASDAQ: MAZE

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization declines year over year

Q1 FY2026 depreciation & amortization of $444K fell 35.1% year over year, behind the -28.6% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 11.0% from the prior quarter. Over 3 fiscal years it compounded at -14.3% a year.

Context

  • Depreciation & amortization increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -35.1% toward the trailing-twelve-month pace of -28.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$444K-11.0% QoQ
Last fiscal yearDec 2025
$2.4M-27.1% YoY
LTMMar 2026
$2.16M-28.6% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-35.1%——
1 year-27.1%——
3-year CAGR-14.3%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
2.4M USD
Year-over-year change
-27.1%
3-year CAGR
-14.3%

Depreciation & Amortization vs competitors

How MAZE compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -28.6% is the 7th highest of 8, against a peer median of +2.4%.
  • Depreciation & amortization amounts to 10.8% of revenue for MAZE, versus a peer median of 3.9%.
MAZE Competitors
Depreciation & Amortization for MAZE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PTCTPTC Therapeutics, Inc.LTM Jun 2026$55.3M USD+97.1%-33.0%5.5%
TVTXTravere Therapeutics, Inc.LTM Sep 2026$47.58M USD-13.0%+43.1%7.3%
ARDXArdelyx, Inc.LTM Mar 2026$3.37M USD+51.2%+38.8%0.8%
IVAInventiva S.A.FY2025€2.8M EUR-46.2%+47.6%62.4%
MAZEMaze Therapeutics, Inc.LTM Mar 2026$2.16M USD-28.6%-14.3%10.8%
SEPNSepterna, Inc.LTM Sep 2026$1.25M USD-21.5%—1.3%
BIOABioAge Labs, Inc.LTM Mar 2026$239K USD+39.8%+18.2%2.3%
DMACDiaMedica Therapeutics Inc.LTM Mar 2026$43K USD+2.4%+19.8%—
Peer median (excluding MAZE) —+2.4%+29.3%3.9%

Competitors are the stored peer set for MAZE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00167.5M0
Cost of Revenue0002.4M
Gross Profit00167.5M(2.4M)
Gross Margin——100.0%—
Research & Development88.19M73.95M83.5M108.45M
Selling, General & Admin22.83M24.61M26.42M34.45M
Operating Expenses111.03M98.55M109.91M140.5M
Depreciation & Amortization3.82M4.09M3.3M2.4M
EBITDA(111.12M)(96.33M)56.7M(128.72M)
EBITDA Margin——33.9%—
Operating Income(111.03M)(98.55M)57.59M(142.9M)
Operating Margin——34.4%—
Interest Income2.03M1.97M4.65M11.78M
Interest Expense0000
Other Income / Expenses(3.91M)(1.86M)(4.18M)11.78M
Income Before Tax(114.94M)(100.42M)53.4M(131.12M)
Pre-Tax Margin——31.9%—
Income Tax Expense001.17M0
Net Income(114.94M)(100.42M)52.23M(131.12M)
Net Margin——31.2%—
EPS (Basic)(2.63)(2.29)0.08(3.05)
EPS (Diluted)(2.63)(2.29)0.08(3.05)
Weighted Avg Shares43.78M43.78M43.8M42.98M
Weighted Avg Shares (Diluted)43.78M43.78M43.8M42.98M

Maze Therapeutics, Inc.

NASDAQ:MAZE

Intrinsic Alpha fair value

Locked

Current Price

$31.20

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.